Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Other Accumulated Expenses (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Other Accumulated Expenses for 6 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 225.15% to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 225.15% increase, with the full-year FY2024 number at $548458.0, up 1.14% from a year prior.
  • Other Accumulated Expenses was $1.5 million for Q3 2025 at Ensysce Biosciences, up from $1.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $3.7 million in Q3 2021 to a low of $370186.0 in Q2 2024.
  • A 5-year average of $1.4 million and a median of $967077.5 in 2025 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: surged 888.29% in 2021, then plummeted 82.68% in 2024.
  • Ensysce Biosciences' Other Accumulated Expenses stood at $3.4 million in 2021, then crashed by 34.66% to $2.2 million in 2022, then tumbled by 75.65% to $542260.0 in 2023, then grew by 1.14% to $548458.0 in 2024, then surged by 165.03% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Other Accumulated Expenses are $1.5 million (Q3 2025), $1.0 million (Q2 2025), and $888498.0 (Q1 2025).